Early-Stage Lung Cancer Diagnostics Therapy Market

Future Market Insights

Key Insight

The early-stage lung cancer diagnostics therapy market is projected to grow from USD 2.5 billion in 2025 to USD 6.5 billion by 2035, at a CAGR of 10.0%. Non Small-Cell Lung Cancer will dominate with a 72.6% market share, while egfr test will lead the test type segment with a 27.4% share.

October 01, 2025

Anurag Sharma

275 Pages

Cite this Report

Early-Stage Lung Cancer Diagnostics Therapy Market

https://www.futuremarketinsights.com/reports/early-stage-lung-cancer-diagnostics-therapy-market

License

Buy Now

Summary ToC Companies

Key Players

Abbott Laboratories
T. Rowe Price
Illumina
NanoString Technologies
NeoGenomics Laboratories
QIAGEN N.V
Quest Diagnostics
Thermo Fischer Scientific Inc

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Early-Stage Lung Cancer Diagnostics Therapy Market

Key Players

Similar Industry Reports